A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)
100 Clinical Results associated with Intrexon T1D Partners LLC
0 Patents (Medical) associated with Intrexon T1D Partners LLC
100 Deals associated with Intrexon T1D Partners LLC
100 Translational Medicine associated with Intrexon T1D Partners LLC